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Summary. Mycobacterium tuberculosis
isolates from 104 south Indian patients,
including 52 sensitive to Streptomycin (S),
Isoniazid, (H) and Rifampicin (R), and 52
resistant to SHR/HR were tested for their in
vitro susceptibility to Ciprofloxacin and
Ofloxacin on Lowenstein-Jensen medium. The
  geometric mean for minimal inhibitory
 concentration (MIC) of Ciprofloxacin was 2.00
mcg/ml for sensitive strains and 2.17 mcg/ml
for resistant strains, the overall mean being
2.08 mcg/ml. Considering Ofloxacin, the MICs
for the different categories of strains were 
again similar, there being no difference 
 between sensitive and resistant strains, the
geometric means being 2.00 and 2.05 mcg/ml,
 respectively.  
Introduction
Despite the rapid advances in treatment and
the availability of effective short course
chemotherapy regimens, tuberculosis continues
to be a common disease in the community.
Tuberculosis is gaining increasing clinical
relevance also because of its association with
  HIV infection.1 Treatment for disease due to
drug-resistant M. tuberculosis is more toxic, more
expensive and not as successful as in disease due
to drug-sensitive organisms.2 Effective treatment
of patients with multi drug resistant organisms
will be greatly facilitated by the development of
newer anti-tuberculosis drugs.
Interest in the quinolone group of drugs has
grown during the last decade with the
development of new derivatives such as
Norfloxacin, Pefloxacin, Ofloxacin, Enoxacin,
Lomefloxacin and Ciprofloxacin. Of these,
Ciprofloxacin is among those with the lowest
minimal inhibitory concentration (MIC) against
M. tuberculosis3 and is more active than
Norfloxacin and Enoxacin. 4,5 A recent study at
Tuberculosis Research Centre, Madras has given
promising results with Ciprofloxacin on both
drug-resistant and drug-sensitive isolates of M.
Tuberculosis, in vitro.6
Ofloxacin has been reported to be active both
in vitro and in vivo against mycobacteria.7 It was,
therefore, proposed to test the in vitro activity of
Ofloxacin on south Indian isolates of M.
tuberculosis and compare it with that of
Ciprofloxacin. The results of this investigation
are reported in this paper.
Material and Methods
Strains : A total of 104 clinical isolates of M.
tuberculosis from as many patients was tested.
These included 52 isolates sensitive to
Streptomycin (S), Isoniazid (H) and Rifampicin
(R), and 52 resistant to SHR or HR. The
standard sensitive strain M. tuberculosis H37Rv
was also tested.
Drug concentrations  : Ciprofloxacin and
Ofloxacin were incorporated in Lowenstein
Jensen (LJ) medium slopes to give final (pre-
inspissation) concentrations of 0.5, 1, 2, 4, 8, 16,
32 and 64 mcg/ml.
Sensitivity testing : A standard suspension (4
mg/ml) of the strains, which were given code
numbers to conceal their identity, was inoculated
with a 3mm loop on to 2 drug free LJ slopes and
one LJ slope each, with the different
oncentrations of the drugs. All slopes were
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Table 1. Minimal inhibitory concentrations of
Ciprofloxacin against south Indian isolates of
M. tuberculosis
No. of MIC* (mcg/ml)
strains
0.5 1 2 4
SHR sensitive 52 1 1127 13
SHR/HR resistant  52  1   4 35 12
Total 104 2 15 62 25
*No strain had an MIC > 4 mcg/ml.
incubated at 37oC. And, at the end of 4 weeks of
incubation, the MIC was determined using the
20-colony end point.8
Results
MIC for Ciprofloxacin : The standard strain,
M. tuberculosis H37Rv, tested on three different
occasions, gave an MIC of 1 mcg/ml.
Considering the strains isolated from patients
(Table l), even though 21% (11/52) of SHR
sensitive strains had an MIC of 1 mcg/ml, as
against 8% (4 out of 52) of SHR/HR resistant
strains, the corresponding proportions with MIC
of 2 mcg/ml were 52% and 67% respectively.
This shift could have been due to experimental
variation since the proportions of strains with an
MIC of 4 mcg/ml were nearly identical. The
geometric mean MICs were 2.00 mcg/ml for
sensitive strains and 2.17 mcg/ml for resistant
strains, the overall mean being 2.08 mcg/ml.
MIC for Ofloxacin : The MIC of Ofloxacin for
M. tuberculosis H37Rv was 1 mcg/ml on the two
occasions tested. The distributions of the MICs
with the two categories of strains were very
similar, their being no difference between
sensitive and resistant strains, the geometric
mean MICs being 2.00 and 2.05 mcg/ml,
respectively (Table 2).
Discussion
Although the currently used treatment
regimens for pulmonary tuberculosis arc quite
effective in patients with drug sensitive
organisms,the patients with drug resistant
Table 2. Minimal inhibitory concentrations of
Ofloxacin against south Indian isolates of M.
tuberculosis
No. of MIC* (mcg/ml)
s t r a i n s  
0.5 1 2 4
SHR sensitive 52 1 833 10
SHR/HR resistant 52 1 7 33 11
Total 104 2 15 66 21
*No strain had an MIC > 4 mcg/ml.
organisms, especially those resistant to Isoniazid  
and Rifampicin, do not respond well to these
regimes.9 In view of the possibility of an increase
in Rifampicin resistance among tuberculosis
patients,there is an urgent need for
investigations with the newer anti-tuberculosis
drugs.10 These newer drugs include the
aminoglycosides,such as Amikacin and
Capreomycin,the long acting Rifampicin
derivatives, the fluoroquinoloncs and
combinations of beta-lactam antibiotics with
bet -lactamase inhibitors.l0’1l
Considering first the aminoglycosides,
although Amikacin is effective against M. avium-
ntracellulare complex, its activity against M.
tuberculosis low and, as such, it might not be
effective in the treatment of disease due to M.
tub rculosis. 11 A recent study from this Centre
revealed that 6% of SHR sensitive and 15% of
SHR/HR resistant strains could be resistant to 
Capreomycin.6 As such, Capreomycin may have
only a limited role in the treatment of patients
with multiple drug-resistant organisms.
The rifamycin derivatives, Rifapentine and
Rifabutin have been reported to be more active
tha  Rifampicin vitro against Rifampicin
sensitive strains. Thus, Arioli and others12
reported a 2 to 10 fold higher activity for
Rifapentine than Rifampicin. Recent studies at
this Centre revealed that although Rifapentine
exhihited a significantly higher activity in
Rifampicin sensitive strains, there was complete
cross resistance in Rifampicin resistant strains.
On the other hand, Rifabutin was not only more
effective than Rifapentinein Rifampicin-
sensitive strains but also a small proportion
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(22%) of Rifampicin-resistant strains were
susceptible to Rifabutin in vitro 13. Thus,
Rifabutin might not only be useful to some
extent in the treatment of disease due to
Rifampicin-resistant organisms but it could
possibly delay the emergence of resistance to the
companion drugs making it particularly
suitable for intermittent chemotherapy due to
its longer half-life,
The introduction of fluoroquinolones has
broadened the range of therapeutic tools used
against mycobacterial diseases. Being a new class
of compounds, there is no cross resistance with
the conventional anti-tuberculosis drugs.9 Of the
various derivatives studied, Ciprofloxacin and
   Ofloxacin have been reported to be most active
in vitro against M. tuberculosis. 3,14,15 However, the
absorption of Ciprofloxacin after oral
administration is poor (mean C max 2.4 mcg/
ml) with a relatively lower mean half life (4.1
hours) compared to that of Ofloxacin (C max :
11 mcg/ml; t 1/2 : 7 hours).16,17 Preliminary
studies have demonstrated that Ofloxacin is
effective against M. tuberculosis, in vitro as well
as in experimental murine tuberculosis.9 In a
recent uncontrolled study conducted by the
Hong Kong Chest Services/British Medical
Research Council,18 it has been reported that
Ofloxacin is a relatively better drug in the
treatment of drug-resistant pulmonary
tuberculosis patients than Rifabutin.
The present investigation revealed that the in
vitro activity of Ofloxacin was similar to that of
Ciprofloxacin, the overall geometric mean MICs
     being 2.03 mcg/ml for Ofloxacin and 2.08 mcg/
ml for Ciprofloxacin. The earlier reported lower
geometric means of MICs from this Centre6 w re
perhaps a reflection of laboratory variations in
medium preparation, batches of drugs used and
doubling dilution concentrations shifting the
mean by one step. It may be observed that the
mean MIC for Ciprofloxacin is only slightly
below the peak serum levels attainable with
therapeutic doses of the drug. However, in
pulmonary and other tissues the drug may attain
levels in excess of those in serum which may be
adequate to inhibit growth of strains.19,20 The
mean MIC of Ofloxacin, however, is far below
the peak serum level of 11 mcg/ml attainable at
normal dosage.16,17. Moreover, our results
showed that the MICs of both Ciprofloxacin and
Ofloxacin were within a narrow range of 1-4
mcg/ml for most of the M. tuberculosis strains
tested. Further, since no differences in
susceptibility to Ciprofloxacin and Ofloxacin
were noted between strains sensitive or resistant
to SHR, it can be concluded that there is no  
cross resistance between these quinolones and
s andard anti-tuberculosis drugs. Earlier
studies at this Centre also showed no
significant differences in the activity of
Ciprofloxacin between SHR sensitive and
resistant strains.6
The present investigation also suggests that
Ciprofloxacin and Ofloxacin might be effective in
the treatment of patients with multiple drug
resistant organisms. But their use in patients
could easily lead to the selection of resistant
mutants. This, in turn, could mean resistance to
the other quinolones, as cross resistance is a well-
known phenomenon among the quinolones.7
Therefore, these quinolones might be useful in
the treatment of multidrugresistant
tuberculosis only if used in judicious
combination with other drugs to which the
strain is sensitive. Thus, the use of
Ciprofloxacin or Ofloxacin in the chemotherapy
of tuberculosis, including their role in the
treatment of failures to standard regimens, can
only be assessed after well planned controlled
clinical trials.
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